Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR) to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19 + tumors. However, the clinical experience with NK cells targeting AML has not been duplicated for adult B-cell (B-ALL).
In this issue of
Rather than relying on the balance between endogenous activating and inhibitory receptors on NK cells to trigger cytolysis of tumor cells, such as B-ALL blasts, investigators have genetically manipulated NK cells to express CARs to redirect specificity. CARs are typically derived from a scFv region of a monoclonal antibody directly recognizing cell surface molecules, for example CD19. The prototypical CAR fuses the scFv exodomain with one or more intracellular chimeric signaling motifs to directly recognize tumor antigen, independent of HLA (5). Because much of the original work using CARs (aptly named "T-body," ref. 6 ) was redirecting the specificity of T cells, the endodomains have been tailored for T-cell signaling. For example, a "first generation" CAR that signals solely through CD3-ζ via its three immunoreceptor tyrosine-based activation motifs (ITAMs), has been coupled in subsequent generations to CD28, 4-1BB, and other costimulatory signaling cytoplasmic domains ( Fig. 1; refs. 7, 8) .
As the ability of CARs to redirect specificity are evaluated in populations of lymphocytes other than T cells, it is probable that the nature of the cell to be manipulated will have to be considered to develop a CAR that is a fully functional molecule capable of activating genetically modified cells for cytolysis, cytokine production and proliferation. Previously, a CD19-specific CAR was shown to activate NK cells through chimeric CD3-ζ and this signaling could be enhanced by the addition of a chimeric 4-1BB co-stimulatory endodomain (9) . This work has now been expanded upon by Altvater and colleagues who generated a second-generation CAR (Fig. 1) to improve NK-cell signaling by modifying their CD19-specific CAR endodomain to include a variant of the signaling lymphocyte activation molecule (SLAM)-related receptor 2B4 (CD244), which improves CAR-dependent activation of ex vivo-propagated NK cells in response to docking with CD19. The cell-surface molecule 2B4, which recognizes CD48, is endogenously expressed on NK cells, including this group's NK cells that have been numerically expanded ex vivo on K562-derived artificial antigen presenting cells. The endogenous 2B4 co-receptor was capable of activating NK cells that express a first-generation CD19-specific CAR when targeting a CD19 + CD48
+ leukemia cell line. To coordinate signaling through CD3-ζ and 2B4 to target primary B-ALL blasts independent of CD48 expression, a next-generation CAR was built that signals through full-length 2B4 cytoplasmic 1 http://clinicaltrials.gov/ct2/show/NCT00698009 domain fused to CD3-ζ (designated CD19-2B4ζ). By understanding that some of the 2B4 signaling domain's four immunoreceptor tyrosine-based switch motifs (ITSMs) may contribute to deleterious signaling, the CD19-specific CAR was further modified to include a truncated 2B4 endodomain, shortened to just signal through the first two ITSMs, and fused to CD3-ζ (designated CD19-t2B4).
Just as autologous CAR + T cells are currently being evaluated in clinical trials, preclinical data are being assembled to adoptively transfer NK cells expressing first and second generation CARs. Donor-derived NK cells may be attractive populations of cells to infuse after allogeneic HSCT to enhance the GVLeffect, for in contrast to T cells, engrafted allogeneic NK cells are not typically considered as instigators of graft-versus-hostdisease (10). However, issues remain about the long-lived potential of genetically modified NK cells, and for that matter ex vivo propagated NK cells in general, to show sustained in vivo persistence and thus survive to exert a long term antitumor effect after adoptive transfer. Nevertheless, infusions of NK cells and CAR + NK cells are now feasible to target both AML and B-ALL, and clinical trials, perhaps concomitant with immunemodulating therapies (11), will determine whether these natural born killers can be called up in the war on cancer.
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